Taking a closer look at the numbers, Comirnaty sales slipped 19% globally to $1.15 billion, the Prevnar franchise experienced a 3% global sales decline to $1.7 billion, and Abrysvo’s performance ...

Eli Lilly is going for gold at the Milano Cortina 2026 Olympic and Paralympic Winter Games. | Eli Lilly is going for gold at ...

UCB has scored an FDA approval for ultra-rare disease treatment Kygevvi, continuing the positive momentum for the Belgian ...

Arcutis tapped the mother-daughter duo to discuss their experiences in the “Free to Be Me” campaign. The goal, according to the company, is to show the emotional and physical burden of inflammatory ...

Insulet is taking diabetes awareness into the workplace. Having found 79% of people with diabetes have faced bias or ...

Teva has issued a voluntary recall of more than 500,000 bottles of the widely used blood pressure medication prazosin ...

One key figure, however, indicates otherwise as sales for Journavx were at $20 million for the period, coming up $3 million ...

A long-running confirmatory trial of two of Sarepta Therapeutics’ Duchenne muscular dystrophy drugs has missed its main goal.

Alvotech, for its part, has run into repeated issues with the FDA at its Icelandic drug plant. Since the company’s biosimilar accord with Teva began, problems at the Reykjavik facility have led to two ...

During the industry’s onshoring rush of the last nine months, Eli Lilly has been among the most aggressive biopharma compa | Eli Lilly is allotting $3 billion to establish an oral medicines ...

For the third straight quarter, AbbVie has jacked up its revenue forecast for 2025. The Illinois drugmaker has raised its guidance by $400 million, now expecting sales to reach $60.9 billion. | ...

For the last several quarters, Gilead Sciences’ earnings calls have been colored by anticipation for the launch of the California drugmaker's long-acting HIV pre-exposure prophylaxis (PrEP) option. | ...